endothelium. In addition to endothelial cells (ECs), most circulating blood cells (BCs), including leukocytes, [14] [15] [16] [17] [18] platelets, 14, 19, 20 and red blood cells (RBCs), 21, 22 also carry eNOS transcript or protein. In RBC, an active red cell eNOS modulates intrinsic erythrocyte deformability, platelet activation, and extraerythrocytic NO• metabolites, such as nitrite. [21] [22] [23] [24] A physiological in vivo effect for circulating eNOS on BP regulation or the formation of the circulating NO• metabolite reservoir has never been evaluated.
The aim of this work was to test in vivo the hypothesis that a functional circulating cell eNOS regulates systemic BP and the formation of the NO• metabolite pool. To limit eNOS functionality to circulating BCs, we used cross-transplantation methodologies with wild-type (WT) and eNOS −/− mice. The resulting chimeric mice were characterized for circulating nitrite levels and BPs (while anesthetized and awake), as well as eNOS expression and activity by Western blotting, real-time reverse transcriptase polymerase chain reaction, flow cytometry, enzymatic NOS activity, chemiluminescence detection, and functional wire myography.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results eNOS −/− Mice Are Hypertensive With Low Circulating Nitrite Levels
To investigate the hypothesis that circulating BC eNOS contributes to the control of BP, systemic BP-systolic and diastolic-was assessed and compared (to 2 decimal places accuracy) in awake mice by radiotelemetry and in anesthetized mice via carotid artery cannulation. Mice with global knockout of functional eNOS (eNOS −/− ) are hypertensive compared with normal WT mice (mean arterial pressure [MAP]: 126±3.18 versus 105.4±2.66 mm Hg; P=0.0016), confirming an important physiological role for eNOS in basal BP regulation ( Figure 1A) , as previously reported for this 13 and all other eNOS −/− strains. 2, 4 They also show lower whole blood (0.72±0.08 µmol/L; Figure 1B ) and plasma (0.38±0.04 µmol/L; Figure 1C ) nitrite levels than WT mice (whole blood: 1.08±0.11 µmol/L and plasma: 0.50±0.54 µmol/L). 1 These values indicate the importance of the eNOS enzyme in regulating BP and nitrite homeostasis.
eNOS −/− Mice Lack Expression and Activity of Red Cell eNOS
RBCs make up the largest cellular compartment in blood and are the circulating reservoir for nitrite. 25 To define the presence of an active eNOS protein in RBCs and its deletion in eNOS −/− mice, immunocytochemistry and immunoprecipitation experiments were performed. Using laser scanning confocal microscopy, eNOS staining was found to strongly localize in RBCs (Ter-119-positive cells) from WT mice ( Figure 1D , left) but not in RBCs from eNOS −/− mice ( Figure 1D , middle). Incubation with IgG was also used to verify that staining was specific for eNOS protein. In these control samples, IgG staining was weakly and homogenously distributed across both cellular and noncellular areas and thus not cell-specific ( Figure 1D , right). Mouse red cell eNOS was further characterized by immunoprecipitation and Western blot analysis. As shown in Figure 1E , eNOS (≈135 KD) is detected in RBCs from WT mice, but not knockout mice, demonstrating electrophoretic characteristics similar to mouse endothelial eNOS from immunoprecipitationenriched samples, crude aortic lysates, and human ECs (Figure 1E , right lane). The densitometry of bands corresponding to eNOS in RBC and aorta of 3 independent gels is shown in Figure 1F .
To assess eNOS activity in WT RBCs, we analyzed conversion of radioactive ( 14 C-labeled) arginine to citrulline. We found that membrane preparations of WT RBCs efficiently converted 14 C-arginine into 14 C-citrulline (0.306±0.107 fmol/min for WT versus 0.107±0.061 fmol/min for eNOS −/− ), as determined by significantly higher (6-fold) reactive counts in the reaction supernatant versus their eNOS −/− counterparts ( Figure 1G ).
Vascular eNOS Expression Is Not Conferred by Bone Marrow Transplantation
WT and eNOS −/− mice were cross-transplanted to elucidate the contribution of BC eNOS to intravascular nitrite formation and physiological BP regulation in vivo. Chimeric animals resulting from this cross-transplantation strategy either expressed eNOS only in BC or in the entire rest of the animal, specifically the vascular EC. These mice are hereafter, respectively, referred to as BC+/EC− and BC−/EC+ chimeras to simply summarize group identity. Control chimeras globally competent (BC+/ EC+) and globally deficient (BC−/EC−) for eNOS were created for comparison purposes using the same BM transplant protocol, with WT marrow transplanted into WT mice and eNOS −/− marrow transplanted into eNOS −/− mice (Figure 2A ). At 6 to 8 weeks after transplantation, flow cytometric analysis of relative CD45 expression (45.1 versus 45.2, mismatched for BM donors and recipients) by peripheral leukocytes confirmed that the BC compartments of cross-transplanted WT and eNOS −/− BM recipients converted >90% to the donor phenotype ( Figure 2B ). Leukocyte and platelet counts were within normal ranges for all chimeras and did not significantly differ between groups ( Table I in Figure 2C ) demonstrated that eNOS expression was undetectable in aortas of BC+/EC− chimeras, similar to untransplanted eNOS −/− (knockout) mice. These data were confirmed by real-time reverse transcriptase polymerase chain reaction ( Figure 2D and 2E), indicating that transfer of WT BM into eNOS −/− recipients does not give rise to vascular eNOS expression. This finding is consistent with a recent lineage tracing study that uses green fluorescent protein to show no significant contribution of transplanted eNOS WT cells to the vascular endothelium of eNOS −/− mice. 26 Thus, vessel walls of the chimeras used in this study retained their pretransplantation phenotypes, whereas blood took on the phenotype of the BM donor. The possibility of a role for compensatory upregulation of vascular cyclooxygenase-1 or cyclooxygenase-2 in the transplanted chimeras was also ruled out; reverse transcriptase polymerase chain reaction confirmed similar cyclooxygenase-1 ( Figure 2F ) and cyclooxygenase-2 ( Figure 2G ) mRNA expression in all 4 chimeric groups.
Vascular Reactivity and cGMP Levels Are Not Impaired by BM Transplantation
To assess the effects of lethal irradiation and BM transplantation on vascular function, wire myography was used to compare vascular reactivity of aortic rings from mice competent for vascular eNOS (WT, BC+/EC+, BC−/EC+). Endothelialindependent (phenylephrine, sodium nitroprusside; Figure 3A and 3C) and endothelial-dependent (acetylcholine; Figure 3B ) relaxation and contraction responses were similar between all 3 groups. Furthermore, cGMP levels were measured in the aortas of cross-transplanted Düsseldorf eNOS −/− chimeras ( Figure 3D ) as a parameter of eNOS-dependent vascular reactivity. Both BC−/EC+ and BC+/EC+ chimeras demonstrated cGMP levels similar to WT controls, indicating that any BP differences of chimeric mice lacking BC eNOS (BC−/EC+), compared with WT controls with global competency for eNOS (BC+/EC+), are not a consequence of altered vascular function from the irradiation and transplantation procedure.
Blood Cell eNOS Rescues eNOS −/− Mice From Hypertension and Low Nitrite Levels
To gain insight into relative contributions of BC versus vessel wall eNOS to circulating NO• derivatives, we measured whole blood ( Figure 4A ) and plasma ( Figure 4B ) nitrite in anesthetized, cross-transplanted chimeras. Transplantation of WT recipients with marrow from eNOS −/− donors decreased circulating nitrite levels by roughly one third compared with irradiated and transplanted WT controls (BC-/EC+ vs BC+/ EC+; plasma: 0.53±0.10 µmol/L versus 0.79±0.07 µmol/L; P<0.05; whole blood: 0.81±0.14 versus 1.19±0.15; P<0.05). Conversely, transplantation of eNOS −/− recipients with marrow from WT donors increased circulating nitrite levels compared with irradiated and transplanted eNOS −/− controls (BC+/ECvs BC−/EC−; plasma: 0.46±0.07 µmol/L versus 0.32±0.02 µmol/L; P=0.08; whole blood: 0.68±0.07 versus 0.49±0.02; P<0.05), indicating that both vascular and BC eNOS are important sources of circulating nitrite in vivo. Figure 4C ). Similar results were obtained by radiotelemetry measurement of BP in awake BC+/EC− chimeras versus their BC−/EC− counterparts ( Figure 5B ; diastolic: P=0.0036; systolic: P=0.0112; MAP: P=0.0056). Although the BP-lowering effect afforded by BC eNOS in otherwise eNOS-deficient mice was low (5 mm Hg), radiotelemetry experiments demonstrated its reproducibility in 2 investigated eNOS −/− strains (Harvard and University of North Carolina; Figure 5C and 5D). In addition, transplantation of eNOS −/− BM into WT background significantly increased BPs relative to BC+/ EC+ chimeras under awake conditions ( Figure 5B ; systolic: P=0.0171; diastolic: P<0.0001; MAP: P=0.0011), again supporting a role for BC eNOS in BP regulation. Differences in the baseline BPs obtained in the anesthetized versus awake BC−/EC+ chimeras suggest an effect for anesthesia ( Figure 4C -4E and Figure 5B ). The data also demonstrate an effect for eNOS in the vascular wall, apparent in anesthetized and awake BC+/EC− chimeras versus their BC+/EC+ counterparts (MAP [mm Hg] of 75.39±2.0 versus 106.1±5.43; P<0.05; Figure 4C and 36-hour MAP (area under the curve) of 4100 versus 3764; P=0.0003; Figure 5A and 5B). In sum, our findings support a role for blood eNOS, in addition to vascular eNOS, in BP regulation.
Given our previous observations of a contribution from both vascular and blood eNOS to intravascular nitrite and the proposed contribution of nitrite to BP regulation, 6, 9, 27 we also explored the relationship between mean plasma and whole blood nitrite levels versus MAP and found an inverse correlation between these parameters across all chimeric groups (plasma: r=−0.91; P<0.05; whole blood: r=−0.91; P=0.05; Figure 4F ). Together, these data support an interrelated role for BC eNOS in nitrite formation and BP regulation. However, the cause and effect remain to be established.
Blood eNOS Lowers BP Independently of Blood iNOS, Platelets, and Leukocytes
Constitutive expression of eNOS in immune cells has been shown to serve overlapping physiological and pathophysiological roles, most notably in activating the proinflammatory profile (iNOS and nuclear factor-κB gene expression) of monocytes/macrophages (human and rodent) in a manner consistent with nanomolar-level NO• production that is Ca 2+ / calmodulin-and cGMP-dependent. 28 The possibility that restoration of immune cell iNOS in an otherwise eNOS-deficient setting, such as the BC+/EC− chimera, could regulate BP was addressed in eNOS −/− mice cross-transplanted with BM from iNOS −/− donors (BC eNOS+ iNOS− /EC−). The resulting chimeric group, possessing blood eNOS but not blood iNOS, maintained a lower BP than the BC−/EC− group, indicating that blood iNOS was not participating in physiological BP control in these mice ( Figure 4G ).
We further investigated the BC type contributing to BP regulation by depleting BC+/BC− chimeras of their platelets or leukocytes. Platelet eNOS is a well-documented antagonist of platelet activation and aggregation. 29 Most leukocytes also express eNOS, [15] [16] [17] [18] although its function in these cells is yet to be clearly defined. To determine whether platelets are the BC source of eNOS involved in physiological BP regulation, BC+/EC− chimeras and their hypertensive counterparts (BC−/ EC−) were pharmacologically depleted of platelets (>90%) using an antithrombocyte serum ( Table II in the online-only Data Supplement). Although platelet depletion lowered MAPs equally in both groups, the BP-lowering effect of red cell eNOS persisted between treated groups (18.45±2.54 mm Hg) to a similar extent as between untreated (platelet-competent) groups (18.80±3.60 mm Hg; Figure 4H ) Leukocytes were also depleted using an anti-CD45 antibody that reacts with the pan-leukocyte antigen CD45 (Ly5), causing clearance of leukocytes from circulation. Treatment of BC+/EC− and BC−/EC− chimeras with this leukodepleting antibody substantially decreased their circulating leukocyte counts by ≥75% (Table II in the online-only Data Supplement). Similar to thrombocytopenia, leukopenia decreased BP in both treated groups but did not eradicate the significant BP-lowering effect of red cell eNOS ( Figure 4H ).
The persistence of lower arterial BPs in BC+/EC− chimeric mice, relative to eNOS −/− controls (BC−/EC−), after platelet-or leukocyte-depletion treatments indicates that platelet-and leukocyte-derived eNOS are not responsible for the BP-modulating effect of circulating blood eNOS and supports a role for a functional red cell eNOS in BP control.
Blood Cell eNOS Effects on BP Are Abolished by NOS Inhibition in Conscious Mice
To further assess the role of blood eNOS availability and function in BP regulation, conscious BP responses to NOS inhibition with L-NAME or repristination with l-arginine were measured in BC+/EC− chimeras via radiotelemetry. Baseline BP (pretreatment) was allowed to stabilize for 10 days after BP sensor implantation. The average BP for the BC+/EC− group was significantly lower than that of its BC−/ EC− counterpart (systolic: P=0.0112; diastolic: P=0.0036; MAP: P=0.0056), strongly supporting a role for blood eNOS in physiological BP regulation ( Figure 5A ). Mice were then treated with L-NAME in the drinking water for 4 days (days 11-14) followed by l-arginine in the drinking water for 3 days (days 15-17). BP averages were calculated for the hours 22:00 to 04:00 on day 10 (baseline), day 14 (L-NAME), and day 17 (l-arginine). Even in the absence of eNOS in the vascular wall and its exclusive presence in blood (BC+/EC−), BP responses to oral L-NAME and oral l-arginine followed a classical pattern ( Figure 5C ): L-NAME consumption increased MAP compared with baseline (3.16±4.77 mm Hg, NS), whereas l-arginine consumption decreased MAP compared with L-NAME (−7.43±4.43 mm Hg; P<0.05). These experiments, performed in chimeras generated from the Harvard eNOS −/− mouse (our usual eNOS-deficient mouse line used for all eNOS −/− experiments except where noted), were repeated in a second group of BC+/EC− chimeras generated from a different, commercially available eNOS −/− mouse (UNC). 4 The UNC BC+/EC− chimeras demonstrated similar significant MAP responses to L-NAME (7.25±3.68 mm Hg; P<0.05) and l-arginine (−11.09±5.97 mm Hg, P<0.05; Figure 5D ). These classical BP responses to the NO• synthase inhibitor and substrate, noted in separate BC+/EC− groups created from different eNOS −/− strains (Figure 5C and 5D) and absent in the UNC-eNOS −/− mice (as shown previously), 30 further support the existence of a BC eNOS that participates in physiological BP regulation. BC−/EC− obtained from the Harvard strain mounted a paradoxical (decreased BP) response to L-NAME ( Figure I in the online-only Data Supplement), as previously shown for Harvard eNOS −/−13 ; however, the differences were not statistically significant. Taken together, these results point to a role for NOS in the decreased BPs observed in the chimeras expressing eNOS only in blood. Until now, conventional wisdom has held that eNOS-mediated control of BP is primarily dependent on eNOS enzyme expressed in the endothelium. These data indicate that BC eNOS also contributes to the regulation of BP.
Discussion
The role of eNOS in vascular endothelium has been shown both in vitro and in vivo to participate in autocrine and paracrine NO• signaling and the control of basal BP. 8 Most circulating BCs, including leukocytes, platelets, and RBCs, have been shown to contain eNOS. [15] [16] [17] [18] 21, 22, 29, 31 It has been suggested that red cell eNOS [21] [22] [23] [24] is capable of producing NO• under normoxic conditions. Data from our laboratory and others have demonstrated NOS-derived effects exerted by RBCs, including inhibition of ADP-induced platelet aggregation, 22 ,32 protection of isolated, perfused hearts from ischemia/ reperfusion injury, 33 as well as decreased RBC-released NO• metabolite (nitrite, nitrate, nitros(yl)ated species) levels in response to NOS inhibition. 22, 24 Circulating angiogenic cells also contain a functional eNOS, but their number in peripheral blood is <0.01% of peripheral blood mononuclear cell numbers (0.0067±0.0097 per 100). [34] [35] [36] However, RBCs are the most abundant cells in blood and transport hemoglobin and contain relatively high levels of nitrite. 25 Hence, it is reasonable to consider a role for RBCs as potential regulators of the circulating NO• pool and BP responses. However, a role for red cell eNOS in NO• signaling remains controversial, and a specific role for BC eNOS in BP regulation has not been investigated previously.
In the present study, cross-transplanted chimeric mice genetically competent or deficient for eNOS in circulating BCs are used to demonstrate a previously unrecognized role for BC eNOS in BP regulation and in vivo nitrite homeostasis. Our data support a persistent blood-derived eNOS effect on BP after in vivo platelet and leukocyte depletion, as well as RBC catalysis of arginine to citrulline and generation of intracellular NO• metabolites. Although these studies provide strong evidence for circulating BCs in NOS-dependent control of BP and nitrite production, Comparisons of moving averages, assessed by 2-way ANOVA, were also statistically significant (P<0.0001).
x axis depicts hours of darkness (gray shade) vs hours of light (white shade). Change in radiotelemetry-detected MAP (mm Hg) in (C) Harvard BC+/EC− chimeras (n=5) and (D) UNC BC+/EC− chimeras (n=5) after oral treatment with L-NAME or l-arginine. Blood pressure data for individual animals shown as solid lines; group averages shown as dashed red line. ‡P<0.05 for L-NAME vs baseline; #P<0.05 for l-arginine vs L-NAME; *P<0.05 using Student t test. BC indicates blood cell; and EC, endothelial cell. definitive clarification of the role of the erythrocyte in this process will require the use of erythroid cell-specific knockout approaches in future studies.
We performed numerous control experiments to test the hypothesis that red cell eNOS regulates BP. We verified that endothelial function/integrity was not affected by our experimental setting, as demonstrated by an absence of change in endothelial-dependent and endothelial-independent vasodilation of aortic rings or aortic cGMP levels relative to the appropriate control group or WT mice. The BP-lowering effects of circulating BC eNOS were not a result of incorporation of BM cells into vascular endothelium, as demonstrated here by the absence of eNOS in Western blot-analyzed BC+/EC− aortas. Consistent with our observation, a recent study involving transplantation of GFP pos (eNOS competent) BM into sublethally irradiated eNOS −/− mice confirmed that BM-derived endothelial progenitor cells do not incorporate into vascular endothelium. 26 Furthermore, we performed control experiments to rule out the contribution of other NOS isoforms to observed changes in BP. We did not detect a compensatory upregulation of other NOS isoforms or the cyclooxygenase 2 gene in the vasculature of the Harvard eNOS −/− mice, a finding that has been previously reported but remains controversial because of reported disparities between different strains of eNOS −/− mice. 13, 30, [37] [38] [39] [40] If other NOS isoforms are responsible for the BP effects we observed in the BC+/EC− chimeras, then a general NOS inhibitor, such as L-NAME, should have reversed those effects. We instead noted that the BC−/ EC− chimera mounted a paradoxical hypotensive response to L-NAME treatment (shown in Figure I in the online-only Data Supplement), a result that has been previously described in the Harvard strain by different groups, 13, 30 whereas the BC+/EC− chimera mounted the classical increased BP response. Paul Huang and others have reported an upregulation of nNOS in the Harvard eNOS knockout mouse 13, 41, 42 and have speculated on its possible role in the mutant's hypotensive BP response to L-NAME treatment. 13 In the presence of a nonspecific NOS inhibitor, such as L-NAME, a compensatory role for nNOS is unlikely to account for our observation. Furthermore, although Paul Kubes' group has shown that nNOS is upregulated in brain and skeletal muscle of the Harvard eNOS knockout mice, it was not sufficient to compensate for eNOS deficiency during H 2 O 2 -stimulated leukocyte infiltration in postcapillary venules. 43 H 2 O 2 has been proposed by several groups as an important endothelium-derived hyperpolarizing factor, but in a NOS-dependent manner. 38, 44 In addition, nonspecific effects of L-NAME treatment have been reported: antagonism of muscarinic acetylcholine receptors 45 and inhibition of cytochrome c reduction in vitro. 46 Indeed, we observed normal endothelial function in WT mice with elevated BP as a result of BC deficiency of eNOS (BC−/EC+ chimeras), an unexpected finding given the general association of elevated BP and endothelial dysfunction.
With regard to a specific role for the RBC in these observations, we did not observe an effect of leukocytes or platelets on eNOS-dependent BP regulation. Reductions in BP in our BC+/ EC− mice were not abrogated by platelet-, leukocyte-, or iNOSdepleting interventions, arguing against a significant role for any of these factors in physiological BP regulation. Although these interventions lowered BP in all groups, the difference in BP observed between the BC+/EC− and BC-/EC− chimeras remained significant and equivalent. The intervention-associated hypotensive responses could be attributable to deficiency of platelet-or neutrophil-derived thromboxane A(2), 47 reactive oxygen species, and augmented prostacyclin levels. 48 Our antileukocyte intervention targeted circulating lymphocytes and neutrophils alike (≥75% depletion). This may be important, given the antihypertensive effects previously shown to be elicited in rats and mice by thymocyte-49 or neutrophil-depleting 50 interventions. It is unlikely that these hypotensive effects could have masked an augmentation in BP because of platelet or leukocyte eNOS deficiency, because the absolute decreases in BP in the BC+/EC− chimera remained constant with and without depletion of leukocytes and platelets.
A recent study evaluating similar chimera experiments reported results that differed from ours. That study observed no BP-reducing effect for GFP pos WT BM when transplanted into eNOS −/− mice. 26 This discrepancy in BP results is likely attributable to differences in study design. Whole-body irradiation and BM transplantation are not without potentially confounding effects, thus the WT and eNOS −/− controls used in this study were also irradiated and BM transplanted, whereas the controls used in the other study were not.
Taken together, the findings from this study point consistently toward a functional circulating RBC eNOS that is active in physiological vasorelaxation and nitrite homeostasis and may make contributions to other as yet unidentified biological processes. If eNOS in blood can contribute to BP regulation and nitrite production, then it is likely to have effects under reparative conditions, such as after myocardial ischemia or stroke. Indeed, circulating BM-derived endothelial progenitor cells have been shown to participate in the neovascularization of jeopardized tissue. 51 A prior study by Ii et al 52 may have relevance to our observations. That study evaluated similar cross-transplantation experiments with BM-recipient mice subjected to experimental myocardial infarction. Cardioprotection was observed in the eNOS −/− mice receiving WT BM, which at the time was ascribed to NO• released by endothelial progenitor cells that had incorporated into ischemic myocardium. However, in that study only a small percentage of the incorporated endothelial progenitor cells and the cardiomyocytes in ischemic myocardium expressed eNOS, suggesting that the cardioprotection may have derived from circulating BC-derived eNOS activity or nitrite. As a final component of these NO•-related regenerative pathways, numerous groups have demonstrated that circulating nitrite can be reduced in the blood to form NO•, regulate hypoxic vasodilation, cytoprotection after ischemia/reperfusion events, and vascular angiogenesis. [9] [10] [11] [53] [54] [55] It is likely that both direct NO• formation and signaling, as well as indirect NO• oxidation to nitrite, contribute to the therapeutic effects of red cell eNOS in angiogenesis, cytoprotection, and BP control.
In summary, the present study provides strong evidence that a circulating blood eNOS participates in nitrite homeostasis and BP regulation under physiological conditions ( Figure 6 ). These findings provide novel insight into mechanisms of BP control that challenge our conventional perspectives on NO• and nitrite signaling in blood, suggesting a more holistic regulation of vascular function, with both the circulating RBCs and the endothelium contributing to vascular homeostasis. The existence of a functional RBC eNOS opens the door to studies addressing the function and dysfunction of blood eNOS in health and disease, such as a role in RBC enzymopathies, hemoglobinopathies, and membranopathies, and in infectious diseases, such as malaria.
Clinical Perspective
Hypertension is a complex multifactorial condition associated with cardiovascular disease. Accumulating evidence points to a correlation between BP and circulating NO• metabolites, such as nitrite. The data presented here demonstrate a role for circulating BC eNOS in nitrite homeostasis and BP regulation under physiological conditions. A cycle of continuous NO• formation in blood might arise from BC eNOS under normoxic conditions and deoxyhemoglobin-mediated reduction of nitrite under hypoxic conditions. This cycle of NO• formation within blood and the vasculature may be impaired in cardiovascular disease, where a generalized eNOS dysfunction is often marked by eNOS uncoupling or protein deficiency. Indeed, recent years have seen anemia and RBC dysfunction identified as independent risk factors for cardiovascular disease. There is a growing recognition that intravascular hemolysis represents a fundamental mechanism for human disease through the release of cell-free plasma hemoglobin that inhibits NO• signaling in the subendothelial layer. It is common to hemoglobinopathies and hemolytic anemia, as well as to the RBC storage lesion of aged blood used in transfusion therapy, and may be driven by red cell eNOS-linked enzymopathies and membranopathies. [56] [57] [58] [59] [60] [61] [62] Thus, our findings may illuminate novel avenues for assaying the general status of eNOS activity and cardiovascular health in the human body. 
